UNICA IRIS Institutional Research Information System

DE LOGU, ALESSANDRO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 172.863
NA - Nord America 10.313
AS - Asia 4.747
SA - Sud America 683
AF - Africa 108
Continente sconosciuto - Info sul continente non disponibili 7
Totale 188.721
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 169.210
US - Stati Uniti d'America 10.116
SG - Singapore 1.878
CN - Cina 1.795
UA - Ucraina 1.050
DE - Germania 610
SE - Svezia 607
FI - Finlandia 560
BR - Brasile 504
VN - Vietnam 350
GB - Regno Unito 301
FR - Francia 277
HK - Hong Kong 137
BD - Bangladesh 118
IN - India 117
KR - Corea 113
CA - Canada 104
MX - Messico 68
AR - Argentina 47
MA - Marocco 46
RU - Federazione Russa 44
EC - Ecuador 41
NL - Olanda 41
IQ - Iraq 38
JP - Giappone 27
CO - Colombia 25
TR - Turchia 25
BE - Belgio 22
ES - Italia 22
ID - Indonesia 22
PL - Polonia 22
ZA - Sudafrica 19
PE - Perù 18
PK - Pakistan 18
VE - Venezuela 15
UZ - Uzbekistan 12
CH - Svizzera 11
IE - Irlanda 11
MD - Moldavia 11
PH - Filippine 11
SA - Arabia Saudita 11
AT - Austria 10
CL - Cile 10
IL - Israele 10
PY - Paraguay 10
EG - Egitto 9
KE - Kenya 8
UY - Uruguay 8
AE - Emirati Arabi Uniti 7
CR - Costa Rica 7
TN - Tunisia 7
AL - Albania 6
AZ - Azerbaigian 6
EU - Europa 6
JM - Giamaica 6
JO - Giordania 6
BO - Bolivia 5
DZ - Algeria 5
IR - Iran 5
MY - Malesia 5
RO - Romania 5
BY - Bielorussia 4
HU - Ungheria 4
KZ - Kazakistan 4
SM - San Marino 4
TW - Taiwan 4
CZ - Repubblica Ceca 3
DK - Danimarca 3
GE - Georgia 3
LT - Lituania 3
MU - Mauritius 3
OM - Oman 3
PT - Portogallo 3
SI - Slovenia 3
SN - Senegal 3
TH - Thailandia 3
TT - Trinidad e Tobago 3
BG - Bulgaria 2
BN - Brunei Darussalam 2
CG - Congo 2
CU - Cuba 2
DO - Repubblica Dominicana 2
EE - Estonia 2
GR - Grecia 2
HR - Croazia 2
KG - Kirghizistan 2
LB - Libano 2
LK - Sri Lanka 2
LV - Lettonia 2
NG - Nigeria 2
NP - Nepal 2
PS - Palestinian Territory 2
QA - Qatar 2
RS - Serbia 2
AF - Afghanistan, Repubblica islamica di 1
AO - Angola 1
BA - Bosnia-Erzegovina 1
BF - Burkina Faso 1
BH - Bahrain 1
BZ - Belize 1
Totale 188.708
Salva come PNG Salva come JPEG
Città #
Cagliari 164.600
Uta 3.055
Singapore 861
Chandler 764
Ashburn 758
San Jose 701
Woodbridge 635
Fairfield 625
Jacksonville 597
Boardman 590
Ann Arbor 491
Dallas 459
Houston 408
Nyköping 406
Helsinki 403
Wilmington 327
Beijing 265
Seattle 259
Munich 257
New York 255
Los Angeles 224
Cambridge 214
Hefei 209
Boston 181
Nanjing 162
Lauterbourg 139
Santa Clara 139
Dearborn 125
Hong Kong 124
Ho Chi Minh City 117
Seoul 112
Milan 110
Council Bluffs 94
Buffalo 91
Rome 87
The Dalles 87
Shanghai 85
Hanoi 79
Redwood City 68
Chicago 67
Shenyang 61
Nanchang 59
Toronto 59
Tianjin 57
Hebei 49
Verona 48
Changsha 45
São Paulo 44
Guangzhou 36
San Diego 35
Atlanta 33
Jiaxing 33
Casablanca 31
Orange 30
Chennai 28
London 28
Washington 28
Zhengzhou 28
Jinan 26
Orem 25
Norwalk 23
Brooklyn 22
Ningbo 21
Bologna 20
Florence 20
Redondo Beach 19
Tokyo 19
Brussels 18
Naples 17
Nuremberg 17
Elk Grove Village 16
Rio de Janeiro 16
Frankfurt am Main 15
Hangzhou 15
Quito 15
Sassari 15
Warsaw 15
Auburn Hills 14
Dhaka 14
Genoa 14
Johannesburg 14
Phoenix 14
Haiphong 13
Mountain View 13
Palermo 12
Saint Petersburg 12
Salt Lake City 12
San Francisco 12
Baghdad 11
Caserta 11
Curitiba 11
Da Nang 11
Denver 11
Jyväskylä 11
Pune 11
Turin 11
Turku 11
Amsterdam 10
Bari 10
Catania 10
Totale 180.589
Salva come PNG Salva come JPEG
Nome #
Exploring the thiazole scaffold for the identification of new agents for the treatment of fluconazole resistant Candida 5.066
Attività antimicobatterica di nuovi S-alchilisotiosemicarbazoni e potenziamento dell'attività di rifabutina, rifampicina e amikacina nei confronti di Mycobacterium avium 4.608
Limonoids from Melia azedarach fruits as inhibitors of flaviviruses and mycobacterium tubercolosis 4.491
2-(2-cycloalkylidene hydrazin-1-yl)-4-aryl-1,3-thiazoles: a promising class of antifungal agents 4.419
Ungeremine effectively targets mammalian as well as bacterial type I and type II topoisomerases 3.501
Antiherpevirus activity of Artemisia arborescens essential oil and inhibition of lateral diffusion in Vero cells 3.068
MmpL3 is the cellular target of the antitubercular pyrrole derivative BM212 2.772
Discovery of in vitro antitubercular agents through in silico ligand-based approaches 2.377
Design, synthesis, SAR and biological investigation of 3-(carboxymethyl)rhodanine and aminothiazole inhibitors of Mycobacterium tuberculosis Zmp1 2.338
Naturally occurring Diels-Alder-type adducts from Morus nigra as potent inhibitors of Mycobacterium tuberculosis protein tyrosine phosphatase B 2.276
New pyrrole derivatives of BM 212: a new class of antimycobacterial agents. Design, synthesis, biological evaluation and study of their mode of action. 2.252
Improved BM212 MmpL3 inhibitor analogue shows efficacy in acute murine model of tuberculosis infection 2.214
Developing pyrrole-derived antimycobacterial agents: a rational lead optimization approach 2.197
Terapia delle infezioni sostenute da Candida spp.: nuovi approcci mediante derivati isotiosemicarbazonici. 2.185
HPLC-DAD-MS analysis and antiviral activity of different extracts and isolated costituents from Bituminaria bituminosa 2.165
Synthesis, biological evaluation and SAR study of novel pyrazole analogues as inhibitors of Mycobacterium tuberculosis 2.114
Imidazole and 1,2,4-triazole-based derivatives gifted with antitubercular activity: Cytotoxicity and computational assessment 2.113
In vitro activity of 2-cyclohexylidenhydrazo-4-phenil-thiazole compared with those of amphotericin b and fluconazole against clinical isolates of Candida spp. and fluconazole-resistant Candida albicans 2.111
Improving the physical chemical properties of a very promising class of pyrrole antimycobacterial agents 2.054
Antimycobacterial activity of new N1-[1-[1-aryl-3-[4-(1H-imidazol-1-yl)phenyl]-3-oxo]propyl]-pyridine-2-carboxamidrazone derivatives 2.018
2-Acylhydrazino-5-arylpyrrole derivatives: Synthesis and antifungal activity evaluation 2.008
In vivo potent BM635 analogue with improved drug-like properties 1.984
1,5-Diaryl-2-ethyl pyrrole derivatives as antimycobacterial agents: design, synthesis and microbiological evaluation 1.973
Rifampicin-loaded liposomes for the passive targeting to alveolar macrophages: in vitro and in vivo evaluation 1.965
null 1.953
null 1.949
Synthesis, biological evaluation, and SAR study of novel pyrazole analogues as inhibitors of Mycobacterium tuberculosis: part 2. Synthesis of rigid pyrazolones 1.940
Synthesis and anti-microbial activity evaluation of some new 1-benzoyl-isothiosemicarbazides. 1.939
The MmpL3 protein is responsible for resistance to BM212, a lead antitubercular drug 1.926
null 1.829
1,5-Diphenylpyrrole derivatives as antimycobacterial agents. Probing the influence on antimycobacterial activity of lipophilic substituents at the phenyl rings 1.824
Nuove strategie per lo sviluppo di farmaci antitubercolari: caratterizzazione di target alternativi e di fattori di virulenza in Mycobacterium tuberculosis 1.804
Design, synthesis and antimycobacterial activity of benzoxazinone derivatives and open-ring analogues: Preliminary data and computational analysis 1.800
Sherris. Microbiologia medica 1.775
null 1.749
Individuazione di nuovi target in MDR e XDR Mycobacterium tuberculosis mediante 1,5-difenil- e 1,5-diaril-2-etil-pirroli per lo sviluppo di nuovi agenti antitubercolari 1.688
Synthesis and anti-microbial activity of isothiosemicarbazones and cyclic analogues 1.669
Synthesis and antimicrobial activity of novel arylidenisothiosemicarbazones 1.665
Attività fungicida di analoghi ciclici isotiosemicarbazonici nei confronti di isolati clinici di Candida spp. 1.652
Synthesis and biological evaluation of new enantiomerically pure azole derivatives as inhibitors of Mycobacterium tuberculosis 1.626
Effetti sulla attività di AmB nei confronti di biofilm di C. albicans in seguito ad esposizione a EM01D2 e fluconazolo. 1.601
Novel N-aryl- and N-heteryl-phenazine-1-carboxamides as potential agents for the treatment of infections sustained by drug-resistant and MDR Mycobacterium tuberculosis 1.564
Phenazine-1-carboxilyc acid derivatives suppressing the RNA polymerase as potential agents for the treatment of infections sustained by drug-resistant and MDR Mycobacterium tuberculosis 1.556
Novel N-aryl- and N-heteryl phenazine-1-carboxamides as potential agents for the treatment of infections sustained by drug-resistant and multidrug-resistant Mycobacterium tuberculosis 1.528
Effetto di Inibitori delle COX-1 e COX-2 sullo sviluppo del biofilm di Candida albicans: studio della associazione di FANS e derivati azolici per la profilassi delle infezioni fungine contratte in ambiente ospedaliero 1.488
Identification of a novel pyrrole derivative endowed with antimycobacterial activity and protection index comparable to that of the current antitubercular drugs streptomycin and rifampin 1.482
Derivati ciclici isotiosemicarbazonici come approccio alternativo nella terapia delle infezioni sostenute da Candida spp. 1.477
Synergistic interaction in vitro between rifabutin and newly synthesized S-alkylisothiosemicarbazones derivatives against mycobacterium avium 1.466
dentification of a new Chemical Class of Potent Antimycobacterial Compounds 1.446
BM 579: a novel pyrrole derivative with improved antimycobacterial activity 1.433
Novel Pyrazole-Containing Compounds Active against Mycobacterium tuberculosis 1.416
Design, synthesis and microbiological characterization of 1,5-diphenyl and 1,5-diaryl-2-ethylpyrrole derivatives as new potential agents of infections sustained by MDR and XDR Mycobacterium tuberculosis. 1.371
Nuovo sistema di fermentazione in semi-solido per la produzione di enzimi cellulosolitici 1.354
Sul trattamento microbiologico delle acque di vegetazione 1.288
Infezioni nosocomiali da Pseudomonas maltophilia in un reparto di terapia intensiva per neonat 1.285
Synergistic interactions in vitro between Rifabutin and newly synthesized s-alkylthiosemicarbazone derivatives against M. avium 1.279
Saggi e dosaggi microbiologici della Farmacopea 1.256
Effetto di FANS sulla formazione di biofilm di Candida albicans e potenziamento della attività di farmaci antifungini 1.247
Studio di un metodo rapido mediante riduzione di XTT per la determinazione della resistenza in Mycobacterium tuberculosis 1.231
BM212 and its derivatives: lead optimization of a new class of antimycobacterial agents. 1.200
Pyrrole derivatives of BM212 as novel antimycobacterial agents Design, synthesis, biological evaluation and study of their mode of action 1.172
null 1.144
An investigation of the biological effect of structural modifications of isothiosemicarbazones and their cyclic analogues 1.135
Antimycobacterial Activiy of New 1,4-Benzoxazine-2-one derivatives and its 2-(arylamino)-4-oxobut-2-enoate, ring-open analogues 1.129
New pyrrole derivatives of BM 212: a new class of antimycobacterial agents.Design, synthesis, biological evaluation and study of their mode of action. 1.115
Design and synthesis of 1,5-diaryl-2-ethyl pyrrole derivatives and their evaluation as antimycobacterial agents 1.096
null 1.070
In vitro antiviral activity of liposomal Artemisia arborescens essential oil 1.044
Derivatives of BM 212: synthesis and biological evaluation of new derivatives with improved antimycobacterial activity. 1.043
Synthesis and biological evaluation of some differently substituted 9,10-anthracenediones 1.043
New pyrrole derivatives of BM 212: lead compound optimization strategy, Tuberculosis drug development. Targets, technologies and trials. 1.016
L’OLIO ESSENZIALE DI ARTEMISIA ARBORESCENS INATTIVA HSV1 E HSV2 E INIBISCE LA DIFFUSIONE LATERALE DI CELLULE VERO 1.014
Synthesis and antimicrobial activity of novel arylideneisothiosemicarbazones 980
null 935
Attività di un derivato isotiosemicarbazonico ciclico nei confronti di biofilm di Candida albicans FLC-S e FLC-R in combinazione con AMB 917
PHISICAL STABILITY OF ARTEMISIA ARBORESCENS L. ESSENTIAL OIL LOADED SLN AND IN VITRO ANTIVIRAL ACTIVITY 914
Influenza dell'inclusione liposomiale sull'attività in vitro di miconazolo e ketoconazolo 869
Aumento della sensibilità all’AmB di biofilm di Candida albicans fluconazolo-resistente nell’impiego combinato con derivati ciclici isotiosemicarbazonici 829
null 826
null 818
Effetti dei liposomi sull'attività in vitro di alcuni antifungini 811
L’olio essenziale di Artemisia arborescens inattiva HSV-1 e HSV-2 e inibisce la diffusione laterale in cellule Vero 806
Studio dell’attività di analoghi ciclici isotiosemicarbazonici nei confronti di isolati clinici di Aspergillus spp 769
null 764
Aspetti Microbiologici della Produzione Farmaceutica 756
null 736
In vitro antimycobacterial activity of newly synthesised S-alkylisothiosemicarbazone derivatives and synergistic interactions in combination with rifamycins against Mycobacterium avium 711
Strategie alternative per la profilassi delle infezioni sostenute da Candida albicans contratte in ambiente ospedaliero mediante isotiosemicarbazoni ciclici 709
Isothiosemicarbazones as alternative approach to the therapy of infections sustained by Candida albicans 696
Liposomes as carrier for Artemisia arborescens essential oil: preparation, characterisation and antiviral activity 673
Studio della attività di una nuova classe di isotiosemicarbazoni nei confronti di Aspergillus spp. di isolamento clinico. 661
6-Fluorophenylbenzohydrazides inhibit Mycobacterium tuberculosis growth through alteration of tryptophan biosynthesis 661
Degradazione biologica degli aghi di pino (Pinus Silvester) 656
Attività intramacrofagica di nuovi agenti antitubercolari per il trattamento delle infezioni sostenute da ceppi MDR mediante inibizione selettiva della RNA polimerasi. 646
 and  opiate receptors mediate specific behavioral syndromes from the Substantia Nigra. 628
Saggi e dosaggi microbiologici della Farmacopea 618
Aspetti microbiologici della produzione farmaceutica 614
null 605
PHYSICAL STABILITY OF ARTEMISIA ARBORESCENS ESSENTIAL OIL LOADED SLN AND IN VITRO ANTIVIRAL ACTIVITY 589
Stafilococchi 584
Totale 154.827
Salva come PNG Salva come JPEG
Categoria #
all - tutte 245.158
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 245.158
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.362 0 0 0 0 0 0 0 0 0 0 0 1.362
2021/20228.886 1.427 908 478 567 715 541 389 529 756 769 902 905
2022/202312.524 1.314 1.647 1.447 886 818 1.183 645 1.462 742 620 954 806
2023/202416.879 940 523 1.037 1.211 1.661 3.247 2.625 943 684 1.201 1.491 1.316
2024/202534.953 7.713 11.595 4.674 2.829 1.715 1.663 2.824 277 451 317 443 452
2025/20269.737 490 699 1.088 1.127 500 599 1.264 1.104 663 1.142 685 376
Totale 188.970